KU-55933 (ATM Kinase Inhibitor)

Catalog No.S1092

KU-55933 (ATM Kinase Inhibitor) Chemical Structure

Molecular Weight(MW): 395.49

KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.

Size Price Stock Quantity  
In DMSO USD 112 In stock
USD 70 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 136 Publications

Purity & Quality Control

Choose Selective ATM/ATR Inhibitors

Biological Activity

Description KU-55933 (ATM Kinase Inhibitor) is a potent and specific ATM inhibitor with IC50/Ki of 12.9 nM/2.2 nM in cell-free assays, and is highly selective for ATM as compared to DNA-PK, PI3K/PI4K, ATR and mTOR.
Targets
ATM [1]
(Cell-free assay)
12.9 nM
In vitro

KU-55933 inhibits DNA-PK and PI3K with IC50 of 2.5 μM and 16.6 μM, respectively. Besides, KU-55933 also prevents the activity of mTOR with IC50 of 9.3 μM. KU-55933 is active at the cellular level in ablating a well-characterized ATM-dependent phosphorylation event. KU-55933 has a dose-dependent effect in inhibiting this ATM-dependent phosphorylation event with IC50 of 300 nM. KU-58050 does not prevent the ATM-dependent phosphorylation of p53 serine 15 until a dose of 30 μM. Addition of KU-55933 has no appreciable effects on UV-induced phosphorylation of H2AX on serine 139, NBS1 on serine 343, CHK1 on serine 345, and SMC1 on serine 966. In stark contrast to the UV responses, KU-55933 ablates the ionizing radiation-induced phosphorylation of these ATM substrates. KU-55933 sensitizes HeLa cells to a range of ionizing radiation doses. [1] KU-55933 inhibits the phosphorylation of Akt induced by growth factors in cancer cells. KU-55933 suppresses the proliferation of cancer cells. Furthermore, suppression of ATM by KU-55933 improves survival, probably via prevention of downstream activation of TAp63α. [2]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
DU-145 M4Pn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jZVGlEPTB;Mz6yO|M2OiEQvF2= Mo\IV2FPT0WU
HuO-3N1 MkDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NET5clVKSzVyPUSuNVcyPDJizszN Mlr3V2FPT0WU
LAMA-84 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW\TfJZRUUN3ME20MlU5PDZ3IN88US=> NX7WZXNPW0GQR1XS
CAL-72 NXLnbIxjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnHtTWM2OD13LkS4NFg1KM7:TR?= NYTyPVdGW0GQR1XS
LoVo MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{D6fWlEPTB;Nj65N|I{QSEQvF2= MVTTRW5ITVJ?
HH M{e5WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX5fZJ2UUN3ME24MlI4PjdzIN88US=> MWjTRW5ITVJ?
SK-MEL-3 M1LmVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIj0bnVKSzVyPUiuNlg2PzVizszN M4XWSnNCVkeHUh?=
KM12 M4\5e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVKwZWdIUUN3ME25MlIyOTR{IN88US=> MkHKV2FPT0WU
NCI-H1437 NF3pWo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTlwOEC5O{DPxE1? M{S2eXNCVkeHUh?=
NCI-H1838 M2rhd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW\jUlJEUUN3ME2xNU4yQDZ3IN88US=> M{HUUnNCVkeHUh?=
J-RT3-T3-5 M4HrS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;4TWM2OD1zMT6yOFE4KM7:TR?= MV3TRW5ITVJ?
GOTO M1PRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3WVmNnUUN3ME2xNU43QTl4IN88US=> MYfTRW5ITVJ?
LB2241-RCC NXvm[4NHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm3OFlSUUN3ME2xNU44OTh4IN88US=> NHnhZnNUSU6JRWK=
ES7 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXHJR|UxRTFzLke4PEDPxE1? M1;4T3NCVkeHUh?=
KP-N-YS NGPuW3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX64cZlXUUN3ME2xNk43OzV2IN88US=> MX\TRW5ITVJ?
CAL-12T NGDoOoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DlVmlEPTB;MUOuOlE4KM7:TR?= MkXzV2FPT0WU
COLO-684 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPVTWM2OD1zND6xOVY6KM7:TR?= NWnzd|MxW0GQR1XS
DOK NY\HS4VbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXRT|U6UUN3ME2xOU4{OzJ7IN88US=> NFq1RXJUSU6JRWK=
Hs-578-T MmnZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3\kdmlEPTB;MUWuOFE5OiEQvF2= M1PFZ3NCVkeHUh?=
D-423MG MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWnDSpg3UUN3ME2xOU42OjN4IN88US=> M3TCNnNCVkeHUh?=
DBTRG-05MG Ml;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4ixWmlEPTB;MUWuOlEyOSEQvF2= MYHTRW5ITVJ?
VM-CUB-1 M3jSe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrKT2VJUUN3ME2xOU46QDR7IN88US=> NWWzbZltW0GQR1XS
KG-1 NF7aZoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF4LkC5PVYh|ryP MX3TRW5ITVJ?
8305C NIq2N5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDLTIt6UUN3ME2xOk4yQDh7IN88US=> NGnZNGtUSU6JRWK=
HuH-7 Mlf1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV6xVWVVUUN3ME2xOk4zPjd2IN88US=> NIfqdppUSU6JRWK=
LXF-289 NH\HNmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnuyTWM2OD1zNj6yO|Q4KM7:TR?= NEnLTG1USU6JRWK=
NCI-H1793 NV\XXIdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXP4SYpMUUN3ME2xOk41PzF{IN88US=> NEjzSVRUSU6JRWK=
ChaGo-K-1 M4f5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnSdVlsUUN3ME2xOk43PTZ6IN88US=> NVvNelRVW0GQR1XS
GCIY NYHTfldTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17yTGlEPTB;MU[uO|kxPSEQvF2= Mn6yV2FPT0WU
SK-MEL-28 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LmUmlEPTB;MUeuNFQ4PSEQvF2= M1rwZ3NCVkeHUh?=
NCI-SNU-1 NULEc|VST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGG5PXFKSzVyPUG3MlEzPjlizszN MlvtV2FPT0WU
CTB-1 NE\vOpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUTJR|UxRTF5LkKyOVkh|ryP MmrQV2FPT0WU
NCI-H82 MnfqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHVdVBKSzVyPUG3MlQ2PzNizszN NVLvSoh3W0GQR1XS
HCC2998 Ml[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXvBSWZnUUN3ME2xO{43PzN|IN88US=> NWHpZ41tW0GQR1XS
NCI-H2030 NIO0RWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\0TWM2OD1zOD6xPVk4KM7:TR?= NXn6Vmo6W0GQR1XS
HuP-T3 NYfHRnB{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfPTWM2OD1zOD61PFg5KM7:TR?= NEnZVIxUSU6JRWK=
697 M1m1Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vOOmlEPTB;MUmuNFIxOSEQvF2= NFHDcmJUSU6JRWK=
MLMA MojHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\GT2RpUUN3ME2xPU4xPTV5IN88US=> NEfobo1USU6JRWK=
HCC70 M1PRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEn1[pRKSzVyPUG5MlQ5QSEQvF2= MWHTRW5ITVJ?
A704 MnLMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1[4dmlEPTB;MUmuPFMxPSEQvF2= NELqO2lUSU6JRWK=
D-283MED NVLwU|A5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1jacWlEPTB;MkCuOVM{QSEQvF2= NHGwW2FUSU6JRWK=
U031 NXXtOIVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXWTWM2OD1{MT6xOFg6KM7:TR?= M{mwbnNCVkeHUh?=
HSC-3 NEjvXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTJzLkG4N|Uh|ryP M4nETXNCVkeHUh?=
JVM-3 Ml60S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nQXGlEPTB;MkKuOVA3KM7:TR?= NXvkUnNQW0GQR1XS
Mewo M1;XOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\UTWM2OD1{Mj61NFc{KM7:TR?= NIjwVYlUSU6JRWK=
YH-13 Mm\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojqTWM2OD1{Mj61NVI{KM7:TR?= NIn5c3ZUSU6JRWK=
LB1047-RCC Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PFUWlEPTB;MkKuOVg4QSEQvF2= MX7TRW5ITVJ?
HCC2157 NXPkVW9XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TSNmlEPTB;MkKuPFA2PCEQvF2= NFvkfnBUSU6JRWK=
SNU-449 MoL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWe5UpRmUUN3ME2yNk45PzR6IN88US=> Ml3UV2FPT0WU
Ramos-2G6-4C10 NFjJfY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTJ{Lkm2JO69VQ>? M2r5WHNCVkeHUh?=
CHL-1 M{LVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXH1bmhIUUN3ME2yN{44Ojl{IN88US=> MoPiV2FPT0WU
SK-MEL-30 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYTvNIpCUUN3ME2yOE41PjZ{IN88US=> MmTDV2FPT0WU
PANC-08-13 M2PsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2Ow[WlEPTB;MkWuNFk{QCEQvF2= M13QWnNCVkeHUh?=
QIMR-WIL M4L5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXiyfol5UUN3ME2yOU4yQDV6IN88US=> MlrzV2FPT0WU
BFTC-905 MlXVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoHWTWM2OD1{NT61PVQ1KM7:TR?= NVi4Old2W0GQR1XS
GI-1 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWOxRWc6UUN3ME2yOU44ODV3IN88US=> NVrQcnJmW0GQR1XS
MDA-MB-415 NFPGUlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDIU4NKSzVyPUK2MlUxOzNizszN NFW5[4hUSU6JRWK=
GT3TKB NIXWU3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJ4LkWzOFIh|ryP MXzTRW5ITVJ?
DEL M4\zN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHPbXJKSzVyPUK2Mlg{PTZizszN NG\DRYpUSU6JRWK=
KOSC-2 NHvLfJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfkb3FKSzVyPUK2MlkxPzVizszN NFLyUoZUSU6JRWK=
RVH-421 M{DGemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVz5dIdZUUN3ME2yO{4zQTJzIN88US=> MlLuV2FPT0WU
EW-13 M{\vXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTJ5LkSzNFgh|ryP M1W1eHNCVkeHUh?=
639-V NF20[FdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIr3eoVKSzVyPUK3MlUyOTlizszN MVnTRW5ITVJ?
A2780 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLtVWUxUUN3ME2yO{43PDFizszN MmPFV2FPT0WU
SW982 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJ5LkmwOVIh|ryP Mo\lV2FPT0WU
SW1710 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTJ6LkC5PFEh|ryP NXrIRm8zW0GQR1XS
HCC1569 NWfSRnhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV3LdlRZUUN3ME2yPE41QDl5IN88US=> NFXCc5VUSU6JRWK=
MV-4-11 NHvJdW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LQTWlEPTB;MkiuOVc{PSEQvF2= MXzTRW5ITVJ?
BHT-101 NFX6N4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jpV2lEPTB;MkiuOlU4OiEQvF2= NX7DfWVQW0GQR1XS
Ca9-22 NWe1TXlbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XiPWlEPTB;MkiuO|E1KM7:TR?= M1v4UXNCVkeHUh?=
HAL-01 M1zMRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;jTWM2OD1{OD63OlE2KM7:TR?= MYPTRW5ITVJ?
D-263MG Mmm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTJ7LkO0OEDPxE1? MVLTRW5ITVJ?
NEC8 NHqxd4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTJ7LkW1OFgh|ryP M{j1cnNCVkeHUh?=
EKVX NGXqclhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXPKR3RVUUN3ME2zNU42QDR5IN88US=> M3HR[XNCVkeHUh?=
EM-2 NUnDWYhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mof2TWM2OD1|MT62N|A1KM7:TR?= M1H0eHNCVkeHUh?=
MFM-223 NFPmRZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF2zXnBKSzVyPUOxMlgxQThizszN MVnTRW5ITVJ?
SK-PN-DW NXnXbWNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;Nb3ZKSzVyPUOyMlE1ODZizszN M3v0XHNCVkeHUh?=
HuO9 Mnz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXoOGlXUUN3ME2zNk42Ojh{IN88US=> MojwV2FPT0WU
MHH-PREB-1 NH3KNYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfBU|dKSzVyPUOyMlYzOzRizszN NYqxR2h7W0GQR1XS
OVCAR-4 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTN{LkizOlMh|ryP MkH5V2FPT0WU
NCI-H1648 M3jvTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MY\JR|UxRTN{Lki2OVEh|ryP MkDRV2FPT0WU
MKN1 M2jZRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fTb2lEPTB;M{SuNVExOSEQvF2= MXHTRW5ITVJ?
KYSE-450 NETuSYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTN2Lk[0OFQh|ryP NGXLbHRUSU6JRWK=
ES8 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTN2Lki5O|Uh|ryP NXXUZ2FjW0GQR1XS
MS-1 NXywWm1xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jwNWlEPTB;M{SuPVU2PCEQvF2= MXfTRW5ITVJ?
HOP-92 NULqUmdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGm3R5VKSzVyPUO1MlkzPzdizszN NHPoNohUSU6JRWK=
SKG-IIIa NHfMVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHKTWM2OD1|Nj6yOVYyKM7:TR?= NVzDNIdpW0GQR1XS
TE-11 M2joUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjKc|ZKSzVyPUO2MlUzPDNizszN NE\mXWRUSU6JRWK=
SK-NEP-1 M1fFPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTN5Lk[3OFQh|ryP NVz6dIFxW0GQR1XS
DB Ml30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnqTWM2OD1|Nz65NVg2KM7:TR?= M{fVcnNCVkeHUh?=
IA-LM MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF;xVWxKSzVyPUO4MlAzOzlizszN M{XSeXNCVkeHUh?=
COLO-829 NXLUPFdVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\2TIlKSzVyPUO4MlQyPTlizszN NUT0e|NjW0GQR1XS
TGBC11TKB MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTN7LkG0NFgh|ryP NH3sV2dUSU6JRWK=
CAL-51 M1zsPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC3U5J[UUN3ME20NE4xPjF{IN88US=> NVTkdo9bW0GQR1XS
NCI-H2228 M37pbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXpTWM2OD12MD6zOlYzKM7:TR?= MlzMV2FPT0WU
C32 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo[0TWM2OD12MD60NFI1KM7:TR?= M4nYfHNCVkeHUh?=
KU-19-19 NYTP[mc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvlWlNKSzVyPUSwMlc3QDNizszN NFO4dmtUSU6JRWK=
KNS-62 MkTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NULRVZpNUUN3ME20NE45OzhzIN88US=> M13aeXNCVkeHUh?=
FADU NHK4R|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYr0ToZXUUN3ME20NU4zPTB{IN88US=> MkfDV2FPT0WU
CAL-33 M1noVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjI[WxKSzVyPUSyMlY4PDlizszN M{HMW3NCVkeHUh?=
CHP-134 MkTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPnTWM2OD12Mj64OFk3KM7:TR?= NILJ[WRUSU6JRWK=
HDLM-2 M362Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;ZeGlEPTB;NEKuPVA5PCEQvF2= Mo\ZV2FPT0WU
NBsusSR NIXD[pJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGC3eYFKSzVyPUSzMlA4OjVizszN NFTYTVZUSU6JRWK=
SW954 M3\wPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnvBTWM2OD12Mz6xNFU{KM7:TR?= MYrTRW5ITVJ?
HCC1806 NUnu[G1uT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrjTZhyUUN3ME20N{41OTFizszN MmnhV2FPT0WU
VMRC-RCZ MmnaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnzdW9IUUN3ME20N{41PTh4IN88US=> MXTTRW5ITVJ?
A549 M{TjSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrpb4lKSzVyPUSzMlk{OSEQvF2= NFPBe4pUSU6JRWK=
NKM-1 Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXvdHdKSzVyPUSzMlk2PThizszN M{npXHNCVkeHUh?=
DMS-273 NGLKVI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTR2Lke1Olch|ryP MX\TRW5ITVJ?
TYK-nu MlPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWK5PGlIUUN3ME20OU4yOjN2IN88US=> MUXTRW5ITVJ?
KALS-1 M33CPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTR3LkG0OkDPxE1? Mk\DV2FPT0WU
A101D M2XacGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjuN2pKSzVyPUS1MlQ1PTZizszN NUWxdIV4W0GQR1XS
G-361 NH\1PVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknQTWM2OD12Nj6yNVM5KM7:TR?= Mne1V2FPT0WU
KARPAS-299 MlTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mon2TWM2OD12Nj6zOVE3KM7:TR?= MWrTRW5ITVJ?
RS4-11 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPuS2RKSzVyPUS2MlU1OiEQvF2= MWnTRW5ITVJ?
HT-1376 M3HUe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTOTWM2OD12Nj63OFI3KM7:TR?= MkC3V2FPT0WU
SK-N-AS NVvubpBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTR4Lke4NlIh|ryP NVjiNVJkW0GQR1XS
MG-63 NIXRdmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVr5Z3ZoUUN3ME20Ok46ODN4IN88US=> NFnldWVUSU6JRWK=
EPLC-272H NYC2V2x[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTR4Lkm1NFMh|ryP MmrrV2FPT0WU
BALL-1 NWDydXhZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2n3O2lEPTB;NEeuPFMzKM7:TR?= NHvKOJdUSU6JRWK=
LCLC-97TM1 M3zsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHFVoVJUUN3ME20PE4zODJizszN MX;TRW5ITVJ?
HO-1-N-1 M3zCRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\3R29CUUN3ME20PE46Pjd4IN88US=> M3jSXXNCVkeHUh?=
MFE-280 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4O1TmlEPTB;NEmuOFYyPyEQvF2= NH[2OnlUSU6JRWK=
NCI-H526 NVrxSXA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlK1TWM2OD12OT64NVY{KM7:TR?= MWnTRW5ITVJ?
D-566MG NGXOPG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYD6dmg4UUN3ME20PU46ODl4IN88US=> NVzFW5JjW0GQR1XS
BB30-HNC M2S2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\aTWM2OD12OT65OFk5KM7:TR?= MlnIV2FPT0WU
SK-N-DZ NUDSNFJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XKNGlEPTB;NUCuNFQ5OSEQvF2= NYTSTZBVW0GQR1XS
HepG2  MoC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUmxNOKh|ryP NGG2bYwzPCCq MUTicI9kc3NiU1OtTWlKOy2rbnT1Z4VlKFNicHjhd4Uh[XK{ZYP0 M2nVV|I2PTJ5MUKz
HepG2  NWXmellzTnWwY4Tpc44hSXO|YYm= M4nU[FExyqEQvF2= NUXQTW9lOjRiaB?= NHLqbm5{fXCycnXzd4V{KHSqZTDwbI9{eGixconsZZRqd26|IH;mJGFVVSCxbjDT[ZIyQThzLDDDbIsyKG:wIGPldlM1PSxiQ3jrNkBwdiCWaIK2PEwh[W6mIFPkb|Ihd25iVInyNVUhcW6mdXPl[EBjgSCVQz3JTWk{ NHfYWmgzPTV{N{GyNy=>
KATO III  M{L2fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjkWmMzNjVxNT:3MlUh|ryP NYHrTHBJTE2VTx?= M1\2NoVvcGGwY3XzJJRp\SC2b4jpZ4l1gSCxZjDvcIFx[XKrYh?= MorrNlQ5PDF5MUi=
hTCEpi MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnLRNVAh|ryP NIPF[|BFVVOR NX;VTVl3eHKndnXueJMhfGinIHP5eI9x[XSqaXOg[YZn\WO2IH;mJGhUXi1z MWGyOFM4ODh|NR?=
MCF10A M3P0Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXqxNEDPxE1? NGrsPWIzPCCq MkX3SG1UVw>? MmT5dI91\W62aXH0[ZMhfGinIHP5eI91d3irY3n0fUBw\iCJQR?= M2PDclI1OTVyNUm1
HL-60  NGf4OlRHfW6ldHnvckBCe3OjeR?= MUixNEDPxE1? MkXFNE42KGh? MoftSG1UVw>? NEHzbFVz\WS3Y3XzJJBpd3OyaH;yfYxifGmxbjDv[kBEcGt{wrC= MlnINlM6OzR2MUG=
MCF-7 NHTqPY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzOUpkyNTFyMN88US=> MYeyOEBp NYfm[W9DTkKV NXXjbZQycW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbh?= NEfvWWczOzF6NUO0Oy=>
HeLa  NX\jWGVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;qNU0yODEQvF2= M4jjblI1KGh? NIXJVHJHSlN? NYrQNZhncW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbh?= Mnv5NlMyQDV|NEe=
SH-SY5Y NYLxemZbTnWwY4Tpc44hSXO|YYm= NUnhXY5MOTEEoN88UeKh MYGyOEBp MmO2bY5pcWKrdIOgZ4xqd3G3aX7vcE1qdmS3Y3XkJJBpd3OyaH;yfYxifGmxbjDv[kBxPTN? MVeyNlYzPzJ7NB?=
IMR-32 M4TV[WZ2dmO2aX;uJGF{e2G7 M1Xnb|ExyqEQvF5CpC=> MXiyOEBp NGS2VWhqdmirYnn0d{BkdGmxcYXpco9tNWmwZIXj[YQheGixc4Doc5J6dGG2aX;uJI9nKHB3Mx?= M4rubFIzPjJ5Mkm0
A549 NFzldlZHfW6ldHnvckBCe3OjeR?= MnXLNVDDqM7:TdMg NILlTnMyKGh? MoL4d5VxeHKnc4Pld{BP[W6xLVPvMYlv\HWlZXSgdFU{KGGlY4XteYxifGmxbh?= MX:yNlU2QTN{MR?=
T47D  NYDJdoQxTnWwY4Tpc44hSXO|YYm= NGDSRY4zOMLibV2= NHLY[I0zPCCq NFTFcY5FVVOR MlnMdJJmfmWwdIOgTXIucW6mdXPl[EBl\We{YXTheIlwdiCxZjDJ{tpD|rF? M1LB[FIyOTR2OEC1
A29 MEF MUjGeY5kfGmxbjDBd5NigQ>? NFS5VZcyOMLizszNxsA> NFf6c3YycA>? MoXwZoxw[2u|wrD0bIUheGixc4Doc5J6dGG2aX;uJI9nKEGtdDDheEBU\XJ2N{RCpC=> NWPpXIVMOjByNUO3PFE>
MDA-MB-453  MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGT2dnM2NTRyIN88US=> M{C2WVczKGh? M4PDe2lEPTBib3[gNVAh|ryP MWOyNFA2Ozd6MR?=
PC-3 NVjUfpZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjm[IZFPS12MDFOwG0> M1vxXVczKGh? M{mydGlEPTBib3[gNVAh|ryP NIT4UVAzODB3M{e4NS=>

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p-AKT(Ser473) / p-AKT(Thr308); 

PubMed: 22739265     


Cells were serum-starved for 6 h and treated with KU-55933 (10 µmol/L) for 1 h before treatment with insulin (100 nmol/L) for 45 min. Cells were lysed, and cell lysates were subjected to SDS-PAGE and Western blotting for the detection of phospho-Akt at Se䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖

PARP / Cleaved PARP / Caspase-3 / Cleaved caspase-3 ; 

PubMed: 22739265     


ATM inhibition by KU-55933 induces apoptosis in differentiated but not undifferentiated SH-SY5Y cells. Cells were starved for 6 h in serum-free medium. KU-55933 (10 µmol/L) was added 1 h before insulin (100 nmol/L) treatment. After 3 h of insulin stimulat䲧疝Ỵ疞㧀疜膉痘 瘿�෋ᾰƌ෋à 㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒塚堙ﻺ᎒ꍈ堞빢᎒學堙漸堞圔堙빢᎒圞堙圭堙𢡄玚Wᾰƌ ᾰƌ戤

ATM-S1981 / ATM / p-p53(S15) / p53 ; 

PubMed: 20639198     


Antioxidant and ATM inhibitors blocked phosphorylation of ATM-S1981, Akt-S473, and p53-S15 as stimulated by H2O2 exposure. Cells were treated with 100 μm H2O2 for 30 min in the absence or presence of KU-55933. Whole cell lysates were subjected to Western 䲧疝Ỵ疞㧀疜膉痘 瘿뾠ՂᾰƌՂĀ 㺣痖

p21 / p27 / p53 ; 

PubMed: 20177072     


HMGE cells were incubated for the indicated times with 1 μm KU-55933 or DMSO. Total protein extracts were analyzed by Western blotting for p21WAF1/CIP1, p27KIP1, p53, or β-actin.

22739265 20639198 20177072
Immunofluorescence
p-S824 KAP1 / ZEBRA ; 

PubMed: 28249048     


HH514-16 cells were treated with NaB (upper panel) or NaB plus KU-55933 (1μM; middle panel) or NaB plus Torin1 (0.5μM; lower panel) for 24 hours and stained with anti-phospho KAP1 (S824) plus anti-ZEBRA antibodies and visualized at 1000X magnification.

28249048
In vivo Suppression of ATM-dependent STAT3 activation by KU-55933 enhances TRAIL-mediated apoptosis through up-regulation of surface DR5 expression, whereas suppression of both STAT3 and NF-κB appeares to be involved in down-regulation of cFLIP accompanied by an additional increase in apoptotic levels. The ATM inhibitor KU-55933 affectes TRAIL-mediated apoptosis more strongly than the JAK2 inhibitor, AG490, or overexpression of STAT3β. [3]

Protocol

Kinase Assay:

[1]
- Collapse

Purified enzyme assays:

ATM for use in the in vitro assay is obtained from HeLa nuclear extract by immunoprecipitation with rabbit polyclonal antiserum raised to the COOH-terminal 400 amino acids of ATM in buffer containing 25 mM HEPES (pH 7.4), 2 mM MgCl2, 250 mM KCl, 500 μM EDTA, 100 μM Na3VO4, 10% v/v glycerol, and 0.1% v/v Igepal. ATM-antibody complexes are isolated from nuclear extract by incubating with protein A-Sepharose beads for 1 hour and then through centrifugation to recover the beads. In the well of a 96-well plate, ATM-containing Sepharose beads are incubated with 1 μg of substrate glutathione S-transferase–p53N66 (NH2-terminal 66 amino acids of p53 fused to glutathione S-transferase) in ATM assay buffer [25 mM HEPES (pH 7.4), 75 mM NaCl, 3 mM MgCl2, 2 mM MnCl2, 50 μM Na3VO4, 500 μM DTT, and 5% v/v glycerol] at 37 °C in the presence or absence of inhibitor. After 10 minutes with gentle shaking, ATP is added to a final concentration of 50 μM and the reaction continued at 37 °C for an additional 1 hour. The plate is centrifuged at 250 × g for 10 minutes (4 °C) to remove the ATM-containing beads, and the supernatant is removed and transferred to a white opaque 96-well plate and incubated at room temperature for 1.5 hours to allow glutathione S-transferase-p53N66 binding. This plate is then washed with PBS, blotted dry, and analyzed by a standard ELISA technique with a phospho-serine 15 p53 antibody. The detection of phosphorylated glutathione S-transferase-p53N66 substrate is performed in combination with a goat antimouse horseradish peroxidase-conjugated secondary antibody. Enhanced chemiluminescence solution is used to produce a signal and chemiluminescent detection is carried out.
Cell Research:

[1]
- Collapse
  • Cell lines: U2OS cells
  • Concentrations: 10 μM
  • Incubation Time: 2 hours
  • Method:

    U2OS cells are exposed to ionizing radiation (3, 5, or 15 Gy) or UV (5 or 50 J/m2) and the ATM response determined by Western blot analysis of p53 serine 15 phosphorylation and stabilization of wild-type p53. Whole cell extracts are obtained from each time point, proteins separated by SDS-PAGE, and the ATM-specific increase in phosphorylated serine 15 measured with a p53 phospho-serine 15 specific antibody. Overall p53 stabilization with time is also observed with a p53-specific antibody (DO-1). Similarly, for studying ATM-dependent phosphorylations on H2AX, CHK1, NBS1, and SMC1, the following antibodies are used: CHK1 phospho-serine 345 and NBS1 phospho-serine 343 antibodies. Histone H2A (H-124) and CHK1 antibodies are also used, as well as SMC1 and SMC1 phospho-serine 966 antibodies. For determination of a cellular IC50 for KU-55933, the peak response time for p53 serine 15 phosphorylation of 2 hours is used to monitor inhibition of ATM. KU-55933 is titrated onto cells and preincubated for 1 hour before ionizing radiation. Using scanning densitometry, the percentage inhibition relative to vehicle control is calculated, and the IC50 value is calculated as for the in vitro determinations.


    (Only for Reference)
Animal Research:

[3]
- Collapse
  • Animal Models: BALB/c nu/nu nude mice bearing LU1205 cells
  • Formulation: --
  • Dosages: 10 μM
  • Administration: --
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (83.44 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
5%DMSO+40%PEG300+5%Tween80+50%ddH2O
For best results, use promptly after mixing. 		3.95 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 395.49
Formula

C21H17NO3S2
CAS No. 587871-26-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

ATM/ATR Signaling Pathway Map

ATM/ATR Inhibitors with Unique Features

Related ATM/ATR Products

  • AZD6738(Ceralasertib) New

    AZD6738 is an orally active, and selective ATR kinase inhibitor with IC50 of 1 nM. Phase 1/2.

  • CHIR-99021 (CT99021) New

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs.

  • Dorsomorphin (Compound C) New

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Also inhibits type I BMP receptor activity.

  • VE-821

    VE-821 is a potent and selective ATP competitive inhibitor of ATR with Ki/IC50 of 13 nM/26 nM in cell-free assays, shows inhibition of H2AX phosphorylation, minimal activity against PIKKs ATM, DNA-PK, mTOR and PI3Kγ.

  • KU-60019

    KU-60019 is an improved analogue of KU-55933, with IC50 of 6.3 nM for ATM in cell-free assays, 270- and 1600-fold more selective for ATM than DNA-PK and ATR,and is a highly effective radiosensitizer.

    Features:Improved analog of KU-55933, and is more effective at blocking ATM-mediated DDR events.

  • Berzosertib (VE-822，VX970|M6620)

    VE-822 is an ATR inhibitor with IC50 of 19 nM in HT29 cells.

    Features:VE-822 is a highly selective and potent derivative of the ATR inhibitor VE-821.

  • Chloroquine diphosphate

    Chloroquine diphosphate is a 4-aminoquinoline anti-malarial and anti-rheumatoid agent, also acting as an ATM activator.

  • AZ20

    AZ20 is a novel potent and selective inhibitor of ATR kinase with IC50 of 5 nM in a cell-free assay, 8-fold selectivity over mTOR.

    Features:AZ20 is the first reported inhibitor of ATR protein kinase demonstrating tumor growth inhibition in vivo.

  • CP-466722

    CP-466722 is a potent and reversible ATM inhibitor, does not affect ATR and inhibits PI3K or PIKK family members in cells.

  • ETP-46464

    ETP-46464 is a potent and selective inhibitor of ATR with IC50 of 25 nM.

    Features:Selective ATR inhibitor and particularly toxic to p53-deficient cancer cells. Often used as a pharmacologic probe due to its ideal pharmacological properties.

Tags: buy KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) supplier | purchase KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) cost | KU-55933 (ATM Kinase Inhibitor) manufacturer | order KU-55933 (ATM Kinase Inhibitor) | KU-55933 (ATM Kinase Inhibitor) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID